NCT07114367View on ClinicalTrials.gov

NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Non Hodgkin Lymphoma (NHL)

Interventions

DRUG

NB02 (Poseltinib)

Dose Level 1, Dose Level 2, Dose Level 3

Sponsors

Lead Sponsor

All Listed Sponsors

lead

NOBO Medicine

INDUSTRY

NCT07114367 - NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter